This editorial introduces the second set of articles related to the update of the clinical practice guidelines for mucositis, developed by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). The first set of articles was published in a special section of the July 2019 issue of Supportive Care in Cancer. The July 2019 articles described the methods used [1] and results related to gastrointestinal mucositis [2] , as well as other classes of interventions for oral mucositis including anti-inflammatory agents [3] , photobiomodulation [4] , vitamins, minerals, and nutritional supplements [5] , and protocols categorized as basic oral care [6] . Furthermore, an entire paper was dedicated to advances in the understanding of the pathogenesis of mucositis [7] .
This issue includes another set of articles that are part of the update for the MASCC/ISOO clinical practice guidelines for the management of mucositis. This set focuses on the following topics: growth factors and cytokines [8] , antimicrobials, mucosal coating agents, anesthetics, and analgesics [9] , cryotherapy [10] , and natural and miscellaneous agents [11] . For each of these topics, the literature was reviewed systematically, and new evidence was merged with the evidence published in the previous guideline update [12] . All the data was used to define the up-to-date level of evidence (LoE) and a guideline category: Recommendation, Suggestion, or No Guideline Possible.
For all four topics, new evidence was identified, including evidence for interventions for which guidelines were established in the previous update. The new evidence resulted in three scenarios: (1) the LoE and the guideline statement remained unchanged; (2) the LoE was enhanced and the guideline statement remained unchanged; (3) reversal of the guideline statement. In the section presenting Natural and Miscellaneous Agents, evidence for numerous new agents was identified, and 3 new guidelines were established.
Notwithstanding, the guidelines are based on a thorough systematic review of the literature. As such, interventions reported in clinical trials in the scientific literature were included. The guidelines are not a review or a list of the commercially available interventions. We plan to update the guidelines periodically, and new interventions may be included in the future.
Historically the MASCC/ISOO mucositis guidelines offered clinicians an evidence-based tool that presented the weighted-evidence in a coded and standardized manner. This was a necessity during the decades in which the literature was developing and the scientific data were poor. Thus, the MASCC/ISOO guidelines bridged the gap between the need to provide palliation and the wish for an evidence-based efficient therapy. From the first publication of the MASCC mucositis guidelines [13] , and including the 1st [14] , and 2nd guideline update [12] , the methods applied by the MSG were meticulous [15, 16] . These methods are considered "state-ofthe-art" regarding systematic review methodology and its protocols aligned with statements from leaders of the American Society of Clinical Oncology [17, 18] . Actually, with each guideline update, the methods became stricter. The most recent methods required at least 2 randomized controlled trials (RCTs) to qualify an intervention for a Suggestion type of guideline, and at least one of these RCTs needed to be flawless to reach a Recommendation type of guideline [1] . Although the amount and level of evidence increased dramatically, it is important to recognize that very few interventions reached a Recommendation type of guideline. Furthermore, although the number of RCTs increased, the power of many RCTs was low. Therefore, the need for the clinical practice guidelines remains valid.
The MASCC/ISOO guidelines was established in 2003 and, as mentioned above, is a continuing project. It has progressed simultaneously with the medical community's expectation of high-quality systematic reviews. The establishment of the International Prospective Register of Systematic Reviews (PROSPERO) of the UK National Institute for Health Research is an example of a major upgrade that the concept of systematic reviews underwent. PROSPERO was launched in 2011 and follows the model outlined in the PRISMA statement in 2010. With the endorsement of PROSPERO by the Cochrane Collaboration in 2013, PROSPERO became a synonym for the accepted standard in systematic review. The MASCC/ISOO methodology of systematic reviews progressed in parallel, with similar outcomes. The unique feature of the MASCC/ISOO approach to the systematic review is the translation of the evidence into clinical practice guidelines thereby assuring the practicality of the evidence in the clinical setting. While the MASCC/ISOO clinical practice guidelines are not a meta-analysis, the risk bias and the power of each study are considered and conclusions are based on the best available evidence.
The ultimate goal of the MASCC/ISOO guidelines is to improve the health care of cancer patients. To this end, we need to continue working collaboratively. The publication of the mucositis guideline update is an important link in a chain of actions required to fulfill this goal. Dissemination of the new MASCC/ISOO mucositis guidelines update, implementation of the guidelines in the clinical setting, long-term assessment of its outcomes, and identification of impediments for implementations are important future steps in this chain of actions. The MSG recognizes the implementation may not be universal due to regional variation in the availability of the interventions, regulatory and economic considerations, as well as preferences of patients and clinicians.
The MASCC/ISOO mucositis guideline update reflects the tremendous progress in mucositis research over the years. Although the number of interventions supported by strong evidence has increased since the previous update, it seems that the need for palliative interventions for this cancer therapy complication remains unmet and that there are many questions that warrant additional research.
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Disclaimer The Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Mucositis Guidelines are developed to facilitate the evidence-based management of mucositis. However, clinicians should also use their own judgment in making treatment decisions for individual patients. The guideline authors and the MASCC/ISOO do not guarantee or take responsibility for clinical outcomes in individual patients.
These guidelines refer to the use of the agents listed for the specific indication listed (i.e., the prevention or treatment of mucositis or related symptoms).
